A High-Throughput Screen to Identify LRRK2 Kinase Inhibitors for the Treatment of Parkinson's Disease Using RapidFire Mass Spectrometry

Journal of Biomolecular Screening

Volumn 21, Issue 2, 2016, Pages 145-155

  Leveridge, Melanie ^a   Collier, Lee ^a,c   Edge, Colin ^a   Hardwicke, Phil ^a   Leavens, Bill ^a   Ratcliffe, Steve ^a   Rees, Mike ^a   Stasi, Luigi Piero ^a,b,d   Nadin, Alan ^a   Reith, Alastair D ^a  

^a GLAXOSMITHKLINE   (United Kingdom)

^b GLAXOSMITHKLINE   (China)

^c Babraham Research Campus   (United Kingdom)

^d Nuevolution A/S   (Denmark)

Author keywords

LRRK2; LRRKtide; mass spectrometry; Parkinson's disease; RapidFire

Indexed keywords

ADENOSINE DIPHOSPHATE; ADENOSINE TRIPHOSPHATE; DIMETHYL SULFOXIDE; GUANOSINE TRIPHOSPHATASE; LEUCINE RICH REPEAT KINASE 2; LEUCINE RICH REPEAT KINASE 2 INHIBITOR; PROTEIN KINASE INHIBITOR; UNCLASSIFIED DRUG; COMPLEMENTARY DNA; LRRK2 PROTEIN, HUMAN; PROTEIN SERINE THREONINE KINASE;

ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; HIGH THROUGHPUT SCREENING; MASS SPECTROMETRY; PARKINSON DISEASE; PRIORITY JOURNAL; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL LINE; CHEMISTRY; GENETICS; HUMAN; METABOLISM; MUTATION; PHOSPHORYLATION; PROCEDURES; PROTEIN TERTIARY STRUCTURE; SF9 CELL LINE;

ANIMALS; CELL LINE; DNA, COMPLEMENTARY; GTP PHOSPHOHYDROLASES; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; LEUCINE-RICH REPEAT SERINE-THREONINE PROTEIN KINASE-2; MASS SPECTROMETRY; MUTATION; PARKINSON DISEASE; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; PROTEIN STRUCTURE, TERTIARY; PROTEIN-SERINE-THREONINE KINASES; SF9 CELLS;

EID: 84954506599     PISSN: 10870571     EISSN: 1552454X     Source Type: Journal    
DOI: 10.1177/1087057115606707     Document Type: Article

References (38)

1. Paisan-Ruiz C., Jain S., Whitney Evans E., et al. Cloning of the Gene Containing Mutations That Cause PARK8-Linked Parkinson's Disease. Neuron 2004, 44, 595-600.
2. Guo L., Wang W., Chen S. G., Leucine-Rich Repeat Kinase 2: Relevance to Parkinson's Disease. Int. J. Biochem. Cell Biol. 2006, 38, 1469-1475.
3. Bosgraaf L., Van Haastert P. J., Roc, a RAS/GTPase Domain in Complex Proteins. Biochem. Biophys. Acta 2003, 1643, 5-10.
4. Mata I., Wedemeyer W., Farrer M., et al. LRRK2 in Parkinson's Disease: Protein Domains and Functional Insights. Trends Neurosci. 2006, 29, 286-293.
5. Bonifati V., The LRRK2-G2019S Mutation: Opening a Novel Era in Parkinson's Disease Genetics. Eur. J. Hum. Genet. 2006, 14, 1061-1062.
6. Wang C. D., Chan P., Clinicogenetics of Parkinson's Disease: A Drawing but Not Completed Picture. Neuroimmunol. Neuroinflammation 2014, 1, 115-126.
7. West A., Moore D., Biskup S., et al. Parkinson's Disease-Associated Mutations in Leucine-Rich Repeat Kinase 2 Augment Kinase Activity. Proc. Natl. Acad. Sci. U. S. A. 2005, 102, 16842-16847.
8. Lee B., Shin J. H., VanKampen J., et al. Inhibitors of Leucine-Rich Repeat Kinase-2 Protect against Models of Parkinson's Disease. Nat. Med 2010, 16, 998-1000.
9. Deng X., Choi H., Buhrlage S., et al. Leucine-Rich Repeat Kinase 2 Inhibitors: A Patent Review (2006-2011). Expert Opin. Ther. Patents 2012, 22, 1415-1426.
10. Rankovic Z., CNS Drug Design: Balancing Physicochemical Properties for Optimal Brain Exposure. J. Med. Chem. 2015, 58, 2584-2608.
11. Chico L. K., Van Eldik L. J., Watterson D. M., Targeting Protein Kinases in Central Nervous System Disorders. Nat. Rev. Drug. Discov. 2009, 8, 892-909.
12. Jaleel M., Nichols J., Deak M., et al. LRRK2 Phosphorylates Moesin at Threonine-558: Characterisation of How Parkinson's Disease Mutants Affect Kinase Activity. Biochem. J. 2007, 405, 307-317.
13. Nichols J., Dzamko N., Hutti J., et al. Substrate Specificity and Inhibitors of LRRK2, a Protein Kinase Mutated in Parkinson's Disease. Biochem. J. 2009, 424, 47-60.
14. Pedro L., Padrós J., Beaudet L., et al. Development of a High-Throughput AlphaScreen Assay Measuring Full-Length LRRK2(G2019S) Kinase Activity Using Moesin Protein Substrate. Anal. Biochem. 2010, 404, 45-51.
15. Liu Z., Galemmo R., Fraser K., et al. Unique Functional and Structural Properties of the LRRK2 Protein ATP-Binding Pocket. J. Biol. Chem. 2014, 289, 32937-32951.
16. Hermanson S., Carlson C., Riddle S., et al. Screening for Novel LRRK2 Inhibitors Using a High-Throughput TR-FRET Cellular Assay for LRRK2 Ser935 Phosphorylation. PLoS ONE 2012, 7, e43580.
17. Ma H., Deacon S., Horiuchi K., The Challenge of Selecting Protein Kinase Assays for Lead Discovery Optimisation. Expert Opin. Drug Discov. 2008, 3, 607-621.
18. Kamikawaji S., Ito G., Iwatsubo T., Identification of the Autophosphorylation Sites of LRRK2. Biochemistry 2009, 48, 10963-10975.
19. Dzamko N., Deak M., Hentati F., et al. Inhibition of LRRK2 Kinase Activity Leads to Dephosphorylation of Ser910/Ser935, Disruption of 14-3-3 Binding and Altered Cytoplasmic Localization. Biochem. J. 2010, 430, 405-413.
20. Li X., Wang Q. J., Pan N., et al. Phosphorylation-Dependent 14-3-3 Binding to LRRK2 Is Impaired by Common Mutations of Familial Parkinson's Disease. PLoS ONE 2011, 6, e17153.
21. Schorpp K., Rothenaigner I., Salmina E., et al. Identification of Small-Molecule Frequent Hitters from AlphaScreen High-Throughput Screens. J. Biomol. Screen. 2014, 19, 715-726.
22. Gilsbach B., Kortholt A., Structural Biology of the LRRK2 GTPase and Kinase Domains: Implications for Regulation. Front. Mol. Neurosci. 2014, 7, 32.
23. Berger Z., Smith K., LaVoie J., Membrane Localisation of LRRK2 Is Associated with Increased Formation of the Highly Active LRRK2 Dimer and Changes in Its Phosphorylation. Biochemistry 2010, 49, 5511-5523.
24. Highkin M., Yates M., Nemirovskiy O., et al. High-Throughput Screening Assay for Sphingosine Kinase Inhibitors in Whole Blood Using RapidFire Mass Spectrometry. J. Biomol. Screen. 2011, 16, 272-277.
25. Hutchinson S., Leveridge M., Heathcote M., et al. Enabling Lead Discovery for Histone Lysine Demethylases by High-Throughput RapidFire Mass Spectrometry. J. Biomol. Screen. 2012, 17, 39-48.
26. Nadin A., Hattotuwagama C., Churcher I., Lead-Oriented Synthesis: A New Opportunity for Synthetic Chemistry. Angew. Chem. Int. Ed. 2012, 51, 1114-1122.
27. Lovering F., Bikker J., Humblet C., Escape from Flatland: Increasing Saturation as an Approach to Improving Clinical Success. J. Med. Chem. 2009, 52, 6752-6756.
28. Young R. J., Green D. V. S., Luscombe C. N., et al. Getting Physical in Drug Discovery II: The Impact of Chromatographic Hydrophobicity Measurements and Aromaticity. Drug Discov. Today 2011, 16, 822-830.
29. Baell J. B., Walters M. A., Chemical Con Artists Foil Drug Discovery. Nature 2014, 513, 481-483.
30. Anand V. S., Reichling L. J., Lipinski K., et al. Investigation of Leucine-Rich Repeat Kinase 2: Enzymological Properties and Novel Assays. FEBS J. 2009, 276, 466-478.
31. Deng X., Dzamko N., Prescott A., et al. Characterisation of a Selective Inhibitor of the Parkinson's Disease Kinase LRRK2. Nat. Chem. Biol. 201l, 7, 203-205.
32. Bedford S. T., Chen I. J., Wang Y., et al. Arylpyrrolopyridine Derived Compounds as LRRK2 Inhibitors. WO/2014/170248, 23, 2014.
33. Garofalo A. W., Aubele D. L., Bowers S., et al. Inhibitors of LRRK2 Kinase Activity. WO/2012/162254, 29, 2012.
34. Miller M., Basu K., Demong D., et al. Compounds Inhibiting Leucine-Rich Repeat Kinase Enzyme Activity. WO/2014/137719, 12, 2014.
35. Galemmo R. A., West A. B., Maddry J. A., Triazolopyridazine Compounds, Use as Inhibitors of the Kinase LRRK2, and Methods for Preparation Thereof. WO/2013/166276, 7, 2013.
36. Hopkins A. L., Groom C. R., Alex A., Ligand Efficiency: A Useful Metric for Lead Selection. Drug Discov. Today 2004, 9, 430-431.
37. Leveridge M., Buxton R., Argyrou A., et al. Demonstrating Enhanced Throughput of RapidFire Mass Spectrometry through Multiplexing Using the JmjD2d Demethylase as a Model System. J. Biomol. Screen. 2014, 19, 278-286.
38. Li T., He X., Thomas J. M., et al. A Novel GTP-Binding Inhibitor, FX2149, Attenuates LRRK2 Toxicity in Parkinson's Disease Models. PLoS One 2015, 10, e0122461.